# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316

> **NCT02041221** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sun Pharma Advanced Research Company Limited** · enrollment: 64 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** SPARC1316 Dose 1
- **DRUG:** Placebo
- **DRUG:** SPARC1316 Dose 2
- **DRUG:** SPARC1316 Dose 3
- **DRUG:** SPARC1316 Dose 4
- **DRUG:** SPARC1316 Dose 5

## Key facts

- **NCT ID:** NCT02041221
- **Lead sponsor:** Sun Pharma Advanced Research Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2016-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02041221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02041221, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02041221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*